Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

August 5, 2009

Primary Completion Date

July 8, 2020

Study Completion Date

July 8, 2020

Conditions
ATTR-PN
Interventions
DRUG

Tafamidis

20 mg oral Fx-1006A daily

Trial Locations (9)

21287

Johns Hopkins Hospital, Baltimore

27100

Centro per lo Studio e la Cura delle Amiloidosi Sistemiche IRCCS - Policlinico San Matteo, Pavia

48149

Universitatsklinikum Muenster, Münster

90185

FAP-Teamet Familjar Amyloidos, Umeå

94010

Centre d'Investigation Clinique, Créteil

C1428AQK

FLENI, Buenos Aires

21941-913

Hospital Universitário Clementino Fraga Filho -HUCFF Universidade Federal do Rio de Janeiro, Rio de Jameiro

1649-028

Centro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria, Lisbon

4099-001

Unidade Clinica de Paramiloidose Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António, Porto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY